title: Comparisons of everolimus and Paclitaxel-eluting stents in patients with acute myocardial infarction.
abstract: BACKGROUND
  It has been established that the newer-generation drug-eluting stent (DES) everolimus-eluting stent (EES) is superior to the first-generation DES paclitaxel-eluting stent (PES). However, the advantages of EES over PES in the setting of acute myocardial infarction (AMI) need to be fully elucidated.
  
  
  METHODS
  The present analysis enrolled 2,911 AMI patients receiving PES (n = 1,210) or EES (n = 1,701) in a large-scale, prospective, multicenter Korea Acute Myocardial Infarction Registry (KAMIR). Propensity score matching was used to adjust for baseline biases in clinical and angiographic characteristics, yielding a total of 2,398 patients (1,199 receiving PES and 1,199 receiving EES). Various clinical outcomes at 1 year were compared between the two propensity score matched groups. Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction (Re-MI), or target lesion revascularization (TLR).
  
  
  RESULTS
  Baseline clinical and angiographic characteristics were comparable between the two groups after propensity score matching. Clinical outcomes of the propensity score matched patients showed that the rates of in-hospital and 1-year cardiac and all-cause death were similar between the two groups. But patients in the EES group had significantly lower incidences of Re-MI (1.4% vs 2.8%, P = 0.002), TLR (1.2% vs 3.1%, P = 0.001), TLF (6.4% vs 10.2%, P = 0.001), and probable or definite stent thrombosis (0.3% vs 1.8%, P < 0.001) than did those in the PES group.
  
  
  CONCLUSIONS
  The present propensity matched analysis suggests that the use of EES in the setting of AMI appears to be superior to PES in reducing TLF, and stent thrombosis.
authors.affiliation: Cardiology Department, the Second Hospital of Tianjin Medical University, Tianjin, China.
authors.forename: Kang-Yin
authors.initials: KY
authors.lastname: Chen
authors.forename: Seung-Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Yong-Jian
authors.initials: YJ
authors.lastname: Li
authors.forename: Guang-Ping
authors.initials: GP
authors.lastname: Li
authors.forename: Dong Joo
authors.initials: DJ
authors.lastname: Oh
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Young Jo
authors.initials: YJ
authors.lastname: Kim
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Tae Hoon
authors.initials: TH
authors.lastname: Ahn
mesh_terms: D000368:Aged; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D062645:Percutaneous Coronary Intervention; D057216:Propensity Score; D011446:Prospective Studies; D012042:Registries; D056910:Republic of Korea; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D017239:Paclitaxel